Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth quarter 2024 investor letter. A ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Regeneron (REGN – Research Report) yesterday and set a price target of ...

Bayer has joined its peers among European drugmakers ... while simultaneously addressing the longer-term roadblocks holding us back," he remarked. "The 154 days since March 5th have been pretty ...

Bayer began to focus again on expanding its international activities, focusing mainly on Western Europe and the United States. The company gained an important position in the US pharmaceuticals ...

Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea ...

REGN announces business updates at the J.P. Morgan Healthcare Conference. The company also reports sales for Eylea and Eylea ...

Kerenida is currently approved to slow the progression chronic kidney disease associated with type 2 diabetes.